The commercial availability of Pyzchiva®, which builds on the US launch of Hyrimoz® in July 2023, marks an important step in the Sandoz strategic ambition to become number one in biosimilars in ...
10d
GlobalData on MSNBiosimilars drive Sandoz growth ahead of unclear tariff effects in 2025Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...
Sandoz recently launched Hyrimoz, a biosimilar for Humira, and has over 20 biosimilar assets in pipeline including biosimilars for Tysabri, Prolia/Xgeva, Stelara, and Eylea. In Europe and other ...
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesMEDIA RELEASEFY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in ...
In April, Sandoz leveraged a private-label agreement in the US to accelerate patient switching to its biosimilar; Hyrimoz® (adalimumab) is now the leading adalimumab biosimilar in the US market.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results